CTRI/2024/06/068625尚未招募3 期
A Prospective, Randomized, Double-Blind, Parallel Group, Three Arm, Study to Evaluate the Effectiveness and Safety of Green-Lipped Mussel Oil (GLMO) on Joint Health in Older Adults. - Nil
Great HealthWorks, Inc.0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subject with Osteoarthritis (OA) (Class I-III), according to Kellgren and Lawrence system and confirmed by X-ray, who have been completely withdrawn from their previous analgesics or anti-inflammatory medications or have been newly diagnosed with mild to moderate OA, and who are not currently taking any analgesics or anti-inflammatory medications
- •2.Subjects with a body mass index (BMI) = 29.9 kg/m2
- •3.Subjects willing to and able to perform the treadmill walking test
- •4.Subject willing to and able to complete the questionnaires required for the study
- •5.Females of childbearing age, agree to use approved birth control methods during the study, and have negative urine pregnancy test (UPT) at screening
- •6.Subject understands the study procedures, is ready to comply and provide signed informed consent form (ICF) to participate in the study.
排除标准
- •1. Subjects with any history of fracture involving the study joint or with any other type of arthritis or OA secondary to a known disorder such as rheumatoid arthritis, seronegative spondyloarthropathy, mixed connective tissue disease, collagen vascular disease, and psoriasis.
- •2. Subjects who had surgery, or arthroscopy within three months prior to inclusion
- •3. Subjects with severe bone or joint deformation or condition
- •4. Subjects who have been administered hyaluronic acid injections within six months prior to screening and
- •glucosamine and/or chondroitin containing compounds within seven days prior to the screening visit
- •5. Subjects who have used medications with MMP-inhibitory properties or took corticosteroids within 28 days of Screening Visit.
- •6. Subjects with history of Any chronic health condition,Psychiatric illness, Drug abuse, smoking, abuse or addiction to alcohol, Bariatric surgery or eating disorder such as bulimia or binge eating, Cardiovascular surgery, History of any other major surgery
- •7. Subjects on any medical treatment either systemic or topical which may interfere with the performance of
- •the study treatment
- •8. Subjects who have experienced a known stressful event within the last 6 months such as death in family,
- •accident, hospitalization
- •9. Subjects with a known allergy to herbal products
- •10. Subjects who are pregnant or lactating or nursing
- •11. Known HIV or Hepatitis B positive or any other immuno-compromised state
- •12. Currently participating or having participated in another clinical trial during the last 3 months prior to the
- •beginning of this study
研究者
相似试验
招募中
3 期
A clinical study to assess the potential effect and safety of SUN-CA on the Risk Factors of ObesityCTRI/2017/03/008170Vidya Herbs Pvt Ltd70
进行中（未招募）
3 期
A clinical trial to evaluate the efficacy and safety of CGA-7 on the Risk Factors of Obesity.CTRI/2017/04/008295Vidya Herbs Pvt Ltd
已完成
不适用
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillatio-I48 Atrial fibrillation and flutterAtrial fibrillation and flutterI48PER-025-07BAYER S.A.,
已完成
3 期
A study comparing the efficacy and safety of once-daily oral rivaroxaban with warfarin for the prevention of stroke and embolism in patients with atrial fibrillation.on-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation.Non-central nervous system systemic embolism in subjects with non-valvular atrial fibrillation.Stroke - IschaemicStrokeACTRN12607000214437Bayer Australia Limited14,269
进行中（未招募）
1 期
A Study to Compare the Effect of Eprosartan versus Eprosartan Mesylate on Blood Pressure in Subjects with High Blood PresureEssential HypertensionMedDRA version: 14.1 Level: PT Classification code 10015488 Term: Essential hypertension System Organ Class: 10047065 - Vascular disordersEUCTR2010-019155-22-GBAbbott Healthcare Products B.V.596